Patents Assigned to U.S. Bioscience, Inc.
-
Publication number: 20020132795Abstract: The present invention relates to new uses of S-2-(3-aminopropylamino)ethyl dihydrogen phosphorothioate, (amifostine) and other aminothiol compounds to treat and reverse toxicities caused by therapeutic agents, radiation treatment or diabetes. In particular, the invention provides a method for treating neurotoxicity and nephrotoxicity associated with the administration of chemotherapeutic agents.Type: ApplicationFiled: May 3, 2002Publication date: September 19, 2002Applicant: U.S. Bioscience, Inc.Inventors: Martin Stogniew, David S. Alberts, Edward H. Kaplan
-
Patent number: 6051563Abstract: The present invention provides methods of administering aminoalkyl phosphorothioate and/or aminoalkyl thiol compounds to patients in a manner that significantly reduces or decreases the adverse or undesirable side-effects of the compounds as compared with conventional intravenous administration.Type: GrantFiled: February 12, 1997Date of Patent: April 18, 2000Assignee: U.S. Bioscience, Inc.Inventors: Martin Stogniew, Philip S. Schein
-
Patent number: 6017921Abstract: The present invention provides for a crystalline form of trimetrexate either as a glucuronate, acetate, hydrochloride, methanosulfonate or lactate salt, which can be processed galenically as a stable, well-defined solid substance and processes for producing the crystalline forms. Such crystalline forms allow for prolonged stability in storage and for oral and intravenous administration of the drug.Type: GrantFiled: February 4, 1998Date of Patent: January 25, 2000Assignee: U.S. Bioscience, Inc.Inventors: Paul Kennedy, Ingomar Grafe, Johann Peter Morsdorf, Kurt-Henning Ahrens
-
Patent number: 6017922Abstract: The present invention provides for thermally stable forms of 2,4-diamino-5-methyl-6-[(3,4,5-trimethoxyanilino)methyl] quinazoline, or trimetrexate. A crystalline 2,4-diamino-5-methyl-6-[(3,4,5-trimethoxyanilino)methyl] quinazoline monohydrate, or trimetrexate monohydrate, belonging to the space group P1(#2) and having a triclinic cell with dimensions of about a=7.699 .ANG., b=9.606 .ANG. and c=13.012 .ANG. is disclosed. A novel Schiff base compound, 2,4-diamino-5-methyl-6-[(3,4,5-trimethoxyphenylimino)-methinyl]quinazoline , is also disclosed. The present invention further provides novel methods of producing stable trimetrexate free base compounds, including crystalline trimetrexate monohydrate. The crystalline monohydrate form provides increased stability over the anhydrous form.Type: GrantFiled: May 18, 1998Date of Patent: January 25, 2000Assignee: U.S. Bioscience, Inc.Inventors: Martin Stogniew, Ingomar Grafe, Johann Morsdorf
-
Patent number: 5994409Abstract: The present invention relates to new uses of S-2-(3-aminopropylamino)ethyl dihydrogen phosphorothioate, (amifostine) and other aminothiol compounds to treat and reverse toxicities caused by therapeutic agents, radiation treatment or diabetes. In particular, the invention provides a method for treating neurotoxicity and nephrotoxicity associated with the administration of chemotherapeutic agents.Type: GrantFiled: December 9, 1997Date of Patent: November 30, 1999Assignees: U.S. Bioscience, Inc., The Arizona Board of Regents on behalf of the University of ArizonaInventors: Martin Stogniew, David S. Alberts, Edward H. Kaplan
-
Patent number: 5846958Abstract: The present invention relates to methods of stimulating the growth of hematopoietic progenitor cells. In particular, it relates to the use of thiols and related compounds in stimulating the growth of hematopoietic progenitor cells in vitro and in vivo. Furthermore, the present invention relates to methods of using these compounds for the treatment of marrow failure states and immunodeficient conditions, including but not limited to myelodysplastic syndromes and acquired immunodeficiency syndrome.Type: GrantFiled: February 17, 1995Date of Patent: December 8, 1998Assignees: U.S. Bioscience, Inc., Arizona Board of Regents on Behalf of the University of ArizonaInventors: Robert L. Capizzi, Alan F. List
-
Patent number: 5824664Abstract: Chronic HIV infection is treated by administering to a subject an organic thiophosphate alone or in combination with another anti-HIV or anti-AIDS drug. The organic thiophosphate is preferably WR 151327, a compound with antioxidant and free radical scavenging activities, or a functional derivative or analogue thereof. WR 151327 suppresses induction of HIV expression in chronically infected cells mediated by cytokines such as TNF.alpha. and GM-CSF. Pharmaceutical compositions comprising at least one organic thiophosphate in combination with one or more anti-HIV or anti-AIDS drugs are also disclosed.Type: GrantFiled: March 26, 1993Date of Patent: October 20, 1998Assignees: U.S. Bioscience, Inc., National Institutes of Health, The National Cancer InstituteInventors: Philip S. Schein, Thea Kalebic
-
Patent number: 5716960Abstract: The present invention provides for a crystalline form of trimetrexate either as a glucuronate, acetate, hydrochloride, methanosulfonate or lactate salt, which can be processed galenically as a stable, well-defined solid substance and processes for producing the crystalline forms. Such crystalline forms allow for prolonged stability in storage and for oral and intravenous administration of the drug.Type: GrantFiled: January 13, 1995Date of Patent: February 10, 1998Assignee: U.S. Bioscience Inc. and IndividualsInventors: Paul Kennedy, Ingomar Grafe, Johann Peter Morsdorf, Kurt-Henning Ahrens
-
Patent number: 5591731Abstract: The present invention relates to a sterile, stable vacuum dried crystalline amifostine composition and, optionally, pharmaceutically acceptable excipient(s). Typically, the crystalline compositions of the present invention exhibit enhanced stability at temperatures ranging from about 4.degree. C. to about ambient temperature for a period of at least 2 years relative to existing solid vacuum dried amorphous amifostine preparations. The reconstituted compositions of the present invention are suitable for administration to humans as a radio- or chemoprotecting agent.Type: GrantFiled: February 16, 1995Date of Patent: January 7, 1997Assignee: U.S. Bioscience, Inc.Inventors: Paul E. Kennedy, Roger A. Rajewski, John M. Baldoni
-
Patent number: 5491135Abstract: Compositions and methods are disclosed which utilize the broad spectrum antiviral activity of PALA. This compound and its pharmaceutically acceptable analogs possess potent activity while displaying minimal toxicity and, therefore, are characterized by a relatively high therapeutic index. Compositions optionally containing other therapeutic agents, such as other antiviral agents, are also disclosed and are found to possess synergistic and/or additive antiviral activity.Type: GrantFiled: March 17, 1993Date of Patent: February 13, 1996Assignee: U.S. Bioscience, Inc.Inventor: Herbert A. Blough
-
Patent number: 5424471Abstract: The present invention relates to a sterile, stable vacuum dried crystalline amifostine composition and, optionally, pharmaceutically acceptable excipient(s). Typically, the crystalline compositions of the present invention exhibit enhanced stability at temperatures ranging from about 4.degree. C. to about ambient temperature for a period of at least 2 years relative to existing solid vacuum dried amorphous amifostine preparations. The reconstituted compositions of the present invention are suitable for administration to humans as a radio- or chemoprotecting agent.Type: GrantFiled: July 29, 1993Date of Patent: June 13, 1995Assignee: U.S. Bioscience, Inc.Inventors: Paul E. Kennedy, Roger A. Rajewski, John M. Baldoni
-
Patent number: 5292497Abstract: A method of decreasing the toxicity of chemical therapeutic agents administered in cancer chemotherapy including adminstration to a patient undergoing chemotherapy. This reduction in toxicity can be accomplished by administering an effective amount of S-3-(3-methylaminopropylamino)propyl dihydrogen phosphorothioate. Methods of inducing mucolytic activity and reducing toxicity of acetominophen overdose are also discussed. Such activities are induced through the administration of S-3-(3-methylaminopropylamino)propyl dihydrogen phosphorothioate.Type: GrantFiled: March 29, 1993Date of Patent: March 8, 1994Assignee: U.S. Bioscience, Inc.Inventors: Philip S. Schein, James R. Piper